Liver in sepsis and systemic inflammatory response syndrome

Clinics in Liver Disease

Volumn 6, Issue 4, 2002, Pages 1045-1066

  Szabo, Gyongyi ^a   Romics Jr , Laszlo ^a   Frendl, Gyorgy ^b  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ACTIVATED PROTEIN C; ACUTE PHASE PROTEIN; ANTITHROMBIN III; BLOOD CLOTTING FACTOR; BLOOD CLOTTING INHIBITOR; BRADYKININ ANTAGONIST; CARBON MONOXIDE; CHEMOTACTIC FACTOR; CYTOKINE; ENDOTOXIN; ENTEROTOXIN; FIBRINOGEN; HEAT SHOCK PROTEIN; IBUPROFEN; IMMUNOGLOBULIN G; LIPOPOLYSACCHARIDE; LIPOTEICHOIC ACID; NITRIC OXIDE; PEPTIDOGLYCAN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROSTAGLANDIN; PROTEIN; PROTEINASE; THROMBIN ANTITHROMBIN COMPLEX; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST; THROMBOMODULIN; UNINDEXED DRUG;

APOPTOSIS; BACTERIAL INFECTION; CELL ACTIVITY; CHOLESTASIS; CLINICAL FEATURE; DIAGNOSTIC PROCEDURE; DISEASE COURSE; ENDOTOXEMIA; HEMODYNAMICS; HUMAN; INTRAHEPATIC CHOLESTASIS; KUPFFER CELL; LABORATORY TEST; LIVER DISEASE; METABOLISM; MORTALITY; NONHUMAN; PROTEIN BINDING; REVIEW; SEPSIS; SEPTIC SHOCK; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

APOPTOSIS; CARBON MONOXIDE; CHOLESTASIS; CYTOKINES; HEAT-SHOCK PROTEINS; HEMODYNAMIC PROCESSES; HUMANS; LIPOPOLYSACCHARIDES; LIVER DISEASES; NITRIC OXIDE; SEPSIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 0036867195     PISSN: 10893261     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1089-3261(02)00058-2     Document Type: Review

References (91)

1. Astiz ME, Rackow EC. Septic shock. Lancet 1998;351:1501-5.
2. Rangel-Fausto M, Pittet D, Costigan M. The natural history of the systemic inflammatory response syndrome (SIRS): A prospective study. JAMA 1995;273:117-23.
3. Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis: ACCP/SCCM Consensus Conference Committee. Chest 1992;101:1644-55.
4. Plank LD, Hill GL. Sequential metabolic changes following induction of systemic inflammatory response in patients with severe sepsis or major blunt trauma. World J Surg 2000;24:630-8.
5. Brun-Buisson C, et al. Incidence, risk factors, and outcome of severe sepsis and septic shock in adults. JAMA 1995;274:968-74.
6. Beutler B, Poltorak A. Sepsis and evolution of the innate immune response. Crit Care Med 2000;29:S2-7.
7. Janeway JCA, Medzhitov R. Introduction: The role of innate immunity in the adaptive innate response. Semin Immunol 1998;10:349-50.
8. Pastor CM, Billiar TR, Losser M-R, et al. Liver injury during sepsis. J Crit Care 1995;10:183-97.
9. Fukui H, Kitano H, Okamoto Y, et al. Interaction of Kupffer cells to splenic macrophages and hepatocytes in endotoxin clearance: Effect of alcohol. J Gastroenterol Hepatol 1995;10(suppl):S31-4.
10. Katz S, Jimenez MA, Lehmkuhler WE, et al. Liver bacterial clearance following hepatic artery ligation and portacaval shunt. J Surg Res 1991;51:267-70.
11. Dhainaut J-F, Marin N, Mignon A, et al. Hepatic response to sepsis: Interaction between coagulation and inflammatory processes. Crit Care Med 2001;29:S42-7.
12. Maynard ND, Bihari DJ, Neil Dalton R, et al. Liver function and splanchnic ischemia in critically iii patients. Chest 1997;111:180-7.
13. Rolando N, Wade J, Davalos M, et al. The systemic inflammatory response syndrome in acute liver failure. Hepatology 2000;32:734-9.
14. Wang XD, Soltesz V, Andersson R, et al. Bacterial translocation in acute liver failure induced by 90 percent hepatectomy in the rat. Br J Surg 1993;80:66-71.
15. Moseley RH. Sepsis and cholestasis. Clin Liver Dis 1999;3:465-75.
16. Franson TR, Hierholzer Jr. WJ, LaBrecque DR. Frequency and characteristics of hyperbilirubinemia associated with bacteremia. Rev Infect Dis 1985;7:1-9.
17. Jansen PLM. Early events in sepsis-associated cholestasis. Gastroenterology 1999;116:486-8.
18. Kubitz R, Wettstein M, Warskulat U, et al. Regulation of the multidrug resistance protein 2 in the rat liver by lipopolysaccharide and dexamethasone. Gastroenterology 1999;116:401-10.
19. Mathison JC, Ulevitch RJ. The clearance, tissue distribution, and cellular localization of intravenously injected lipopolysaccharide in rabbits. J Immunol 1979;123:2133-43.
20. Bikhazi AB, Jurjus AR, Kamal MT, et al. Kinetics of lipopolysaccharide clearance by Kupffer and parenchyma cells in perfused rat liver. Comp Biochem Physiol C Pharmacol Toxicol Endocrinol 2001;129:339-48.
21. Nakatani Y, Fukui H, Kitano H, et al. Endotoxin clearance and its relation to hepatic and renal disturbances in rats with liver cirrhosis. Liver 2001;21:64-70.
22. Schumann RR, Lamping N, Hoess A. Interchangeable endotoxin-binding domains in proteins with opposite lipopolysaccharide-dependent activities. J Immunol 1997;159:5599-605.
23. de Haas CJ, van der Zee R, Benaissa-Trouw B, et al. Lipopolysaccharide (LPS)-binding synthetic peptides derived from serum amyloid P component neutralize LPS. Infect Immun 1999;67:2790-6.
24. Munford RS, Dietschy JM. Effects of specific antibodies, hormones, and lipoproteins on bacterial lipopolysaccharides injected into the rat. J Infect Dis 1985;152:177-84.
25. Bellingan G. Leukocytes: Friend or foe? Intensive Care Med 2000;26:S111-8.
26. Van Oosten M, Rensen PCN, Van Amersfoort ES, et al. Apolipoprotein E protects against bacterial lipopolysaccharide-induced lethality. J Biol Chem 2001;276:8820-4.
27. Netea MG, de Bont N, Demacker PNM, et al. Lipoprotein(a) inhibits lipopolysaccharide-induced tumor necrosis factor alpha production by human mononuclear cells. Infect Immun 1998;66:2365-7.
28. Matuschak GM, Rinaldo JE. Organ interactions in the adult respiratory distress syndrome during sepsis: Role of the liver in host defense. Chest 1988;94:400-6.
29. Lautt W. Mechanism and role of intrinsic regulation of hepatic arterial blood flow: Hepatic arterial buffer response. Am J Physiol 1985;G549-56.
30. Hinshaw L, Reins D, Hill R. Response of isolated liver to endotoxin. Can J Physiol Pharmacol 1996;44:529-41.
31. Hill M, McCallum R. Altered transcription regulation of phosphoenolpyruvate carboxykinase in rats following endotoxin treatment. J Clin Invest 1991;88:811-6.
32. Jones C, Titheradge M. The effect oftreatment of rat with bacterial endotoxin on gluconeogenesis and pyruvate metabolism in subsequently isolated hepatocytes. Biochem J 1993;289:169-72.
33. Malmezat T, Breuille D, Capitan P, et al. Glutathione turnover is increased during the acute phase of sepsis in rats. J Nutr 2000;130:1239-46.
34. Koo DJ, Zhou M, Chaudry IH, et al. Plasma α-glutathione S-transferase. Arch Surg 2000;135:198-203.
35. O'Reilly M, Newcomb DE, Remick D. Endotoxin, sepsis, and the primrose path. Shock 1999;12:411-20.
36. Diehl AM. Cytokine regulation of liver injury and repair. Immunol Rev 2000;174:160-71.
37. Carvalho G, et al. Anti-interleukin-8 monoclonal antibody reduces free radical production and improves hemodynamics and survival rate in endotoxic shock in rabbits. Surgery 1997;122:60-8.
38. Karima R, Matsumoto S, Higashi H, et al. The molecular pathogenesis of endotoxic shock and organ failure. Mol Med Today 1999;5:123-32.
39. Todoroki H, Nakamura S, Higure A, et al. Neutrophils express tissue factor in a monkey model of sepsis. Surgery 2000;127:209-16.
40. Marshall JC. Inflammation, coagulopathy, and the pathogenesis of multiple organ dysfunction syndrome. Crit Care Med 2001;29:S99-106.
41. Feder LS, Todaro JA, Laskin DL. Characterization of interleukin-1 and interleukin-6 production by hepatic endothelial cells and macrophages. J Leukoc Biol 1993;53:126-32.
42. Spitzer JA. Cytokine stimulation of nitric oxide formation and differential regulation in hepatocytes and nonparenchymal cells of endotoxemic rats. Hepatology 1994;19:217-28.
43. Lin E, Calvano SE, Lowry SF. Inflammatory cytokines and cell response in surgery. Surgery 2000;127:117-26.
44. van der Poll T, van Deventer SJH. Cytokines and anticytokines in the pathogenesis of sepsis. Infect Dis Clin North Am 1999;13:413-26.
45. Tracey KJ, Beutler B, Lowry SF, et al. Shock and tissue injury induced by recombinant human cachectin. Science 1986;234:470.
46. Brauner JS, Rohde LE, Clausell N. Circulating endothelin-1 and tumor necrosis factor-α: Early predictors of mortality in patients with septic shock. Intensive Care Med 2000;26:305-13.
47. Trinchieri G, Scott P. Interleukin 12: Basic principles and clinical applications [review]. Curr Top Microbiol Immunol 1999;238:57-78.
48. Gunnet C, Heistad D, Berg D, et al. IL-10 deficiency increases superoxide and endothelial dysfunction during inflammation. Am J Physiol 2000;279:H1555-62.
49. Muchamuel T, Menon S, Pisacane P, et al. IL-13 protects mice from lipopolysaccharide-induced lethal endotoxemia: Correlation with down-modulation of TNF-α, IFN-β, and IL-12 production. J Immunol 1997;158:2898.
50. Matsukawa A, Hogaboam CM, Lukacs NW, et al. Expression and contribution of endogenous IL-13 in an experimental model of sepsis. J Immunol 2000;164:2738-44.
51. George J, Roulot D, Koteliansky V, et al. In vivo inhibition of rat stellate cell activation by soluble transforming growth factor beta type II receptor: A potential new therapy for hepatic fibrosis. Proc Natl Acad Sci U S A 1999;96:12719-24.
52. Weisiger RA. Carbon monoxide and sepsis: Is a toxic gas good for your liver? Gastroenterology 2001;120:1288-91.
53. Suematsu M, Ishimura Y. The heme oxygenase-carbon monoxide system: A regulator of hepatobiliary function. Hepatology 2000;31:3-6.
54. Fernandez M, Bonkovsky HL. Increased heme oxygenase-1 gene expression in liver cells and splanchnic organs from portal hypertensive rats. Hepatology 1999;29:1672-9.
55. Fernandez M, Lambrecht RW, Bonkovsky HL. Increased heme oxygenase activity in splanchnic organs from portal hypertensive rats: Role in modulating mesenteric vascular reactivity. J Hepatol 2001;34:812-7.
56. Elbirt KK, Bonkovsky HL. Heme oxygenase: Recent advances in understanding its regulation and role. Proc Assoc Amer Phys 1999;111:438-47.
57. Kyokane T, Norimizu S, Taniai H, et al. Carbon monoxide from heme catabolism protects against hepatobiliary dysfunction in endotoxin-treated rat liver. Gastroenterology 2001;120:1227-40.
58. Cobb JP, Danner RL. Nitric oxide and septic shock. JAMA 1996;276:781-2.
59. Shieh P, Zhou M, Ornan DA, et al. Upregulation of inducible nitric oxide synthase and nitric oxide occurs later than the onset of the hyperdynamic response during sepsis. Shock 2000;13:325-9.
60. Liaudet L, Soriano FG, Szabo C. Biology of nitric oxide signaling. Crit Care Med 2000;28:N37-52.
61. Thijs LG. Coagulation inhibitor replacement in sepsis is a potentially useful clinical approach. Crit Care Med 2000;28:S68-73.
62. Vervloet MG, Thijs LG, Hack CE. Derangements of coagulation and fibrinolysis in critically ill patients with sepsis and septic shock. Semin Thromb Hemost 1998;24:33-44.
63. Jaattela M. Heat shock proteins as cellular lifeguards. Ann Med 1999;31:261-71.
64. Landry J, Chretien P, Lambert H, et al. Heat shock resistance conferred by expression of the human HSP27 gene in rodent cells. J Cell Biol 1989;109:7-15.
65. Oh HJ, Chen X, Subjeck JR. Hsp110 protects heat-denatured proteins and confers cellular thermoresistance. J Biol Chem 1997;272:31636-40.
66. Polla BS, Kantengwa S, Francois D, et al. Mitochondria are selective targets for the protective effects of heat shock against oxidative injury. Proc Natl Acad Sci U S A 1996;93:6458-63.
67. Preville X, Salvemini F, Giraud S, et al. Mammalian small stress proteins protect against oxidative stress through their ability to increase glucose-6-phosphate dehydrogenase activity and by maintaining optimal cellular detoxifying machinery. Exp Cell Res 1999;247:61-78.
68. Hotchkiss R, Nunnally I, Lindquist S, et al. Hyperthermia protects mice against the lethal effects of endotoxin. Am J Physiol 1993;265:R1447-57.
69. Klosterhalfen B, Hauptmann S, Tietze SL, et al. The influence of heat shock protein 70 induction of hemodynamic variables in a porcine model of recurrent endotoxemia. Shock 1997;7:358-63.
70. Suzuki T, Takahashi T, Yamasaki A, et al. Tissue-specific gene expression of heme oxygenase-1 (HO-1) and non-specific δ-aminolevulinate synthase (ALAS-N) in a rat model of septic multiple organ dysfunction syndrome. Biochem Pharmacol 2000;60:275-83.
71. Aderem A, Ulevitch RJ. Toll-like receptors in the induction of the innate immune response. Nature 2000;406:782-7.
72. Takeuchi O, Hoshino K, Kawai T, et al. Differential roles of TLR2 and TLR4 in recognition of gram-negative and gram-positive bacterial cell wall components. Immunity 1999;11:443-51.
73. Muta T, Takeshige K. Essential roles of CD14 and lipopolysaccharide-binding protein for activation of toll-like receptor (TLR)2 as well as TLR4 Reconstitution of TLR2- and TLR4-activation by distinguishable ligands in LPS preparations. Eur J Biochem 2001;268:4580-9.
74. Liu S, Khemlani LS, Shapiro RA, et al. Expression of CD14 by hepatocytes: Upregulation of cytokines during endotoxemia. Infect Immun 1998;66:5089-98.
75. Fleming S, Toratani S, Shea-Donohue T, et al. Pro- and anti-inflammatory gene expression in the murine small intestine and liver after chronic exposure to alcohol. Alcohol Clin Exp Res 2001;25:579-89.
76. Bauerda P, Henkel T. Function and activation of NFκB in the immune system. Annu Rev Immunol 1994;12:141-79.
77. Yang S, Koo DJ, Zhou M, et al. Gut-derived norepinephrine plays a critical role in producing hepatocellular dysfunction during early sepsis. Am J Physiol Gastrointest Liver Physiol 2000;279:G1274-81.
78. Hsu C, Hsu H-K, Yang S-L, et al. Liver protein kinase A activity is decreased during the late hypoglycemic phase of sepsis. Shock 1999;12:274-9.
79. Leist M, Gantner F, Bohlinger I, et al. Tumor necrosis factor-induced hepatocyte apoptosis precedes liver failure in experimental murine shock models. Am J Pathol 1995;146:1220-34.
80. Papathanassoglou EDE, Moynihan JA, Ackerman MH. Does programmed cell death (apoptosis) play a role in the development of multiple organ dysfunctions in critically ill patients? A review and a theoretical framework. Crit Care Med 2000;28:537-49.
81. Chung C-S, Yang S, Song GY, et al. Inhibition of Fas signaling prevents hepatic injury and improves organ blood flow during sepsis. Surgery 2001;130:339-45.
82. Mahidhara R, Billiar TR. Apoptosis in sepsis. Crit Care Med 2000;28:N105-13.
83. Stephens R, Mythen M. Endotoxin immunization. Intensive Care Med 2000;26:S129-36.
84. Ito Y, Lukita-Atmadja W, Machen NW, et al. High doses of intravenous immunoglobulin G enhance Kupffer cell phagocytic function during the late phase of sepsis and endotoxemia in rats. Shock 2000;13:485-91.
85. Rank N, Michel C, Haertel C, et al. N-acetylcysteine increases liver blood flow and improves liver function in septic shock patients: Results of a prospective, randomized, double blind study. Crit Care Med 2000;28:3799-807.
86. Petros A, Lamb G, Leone A, et al. Effects of a nitric oxide synthetase inhibitor in humans with septic shock. Cardiovasc Res 1994;28:34-9.
87. Abraham E, et al. p55 tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock: A randomized controlled multicenter trial. Ro 45-2081 Study Group. JAMA 1997;277:1531-8.
88. Bernard RG, Vincent J-L, Laterre P-F, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699-709.
89. Lorente JA, Garcia-Frade LJ, Landin L. Time course of hemostatic abnormalities in sepsis and its relation to outcome. Chest 1993;103:1536-42.
90. Joyce DE, Gelbert L, Ciaccia A, et al. Gene expression profile of antithrombotic protein C defines new mechanisms modulating inflammation and apoptosis. J Biol Chem 2001;276:11199-203.
91. Warren BL, Eid A, Singer P, et al. High-dose antithrombin III in severe sepsis: A randomized controlled trial. JAMA 2001;286:1869.